We further confirmed our in vitro findings by demonstrating that mice receiving low dose combination treatment of STU and lapatinib displayed reduced mammary tumor growth of HER2+ resistant breast cancer cells compared to either inhibitor alone. This evidence concerns the gene ERBB2 and breast carcinoma.